Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 85
Filter
1.
Epidemiol Infect ; 141(4): 735-44, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23286343

ABSTRACT

The incidence of myocardial infarctions and influenza follow similar seasonal patterns. To determine if acute myocardial infarctions (AMIs) and ischaemic strokes are associated with influenza activity, we built time-series models using data from the Nationwide Inpatient Sample. In these models, we used influenza activity to predict the incidence of AMI and ischaemic stroke. We fitted national models as well as models based on four geographical regions and five age groups. Across all models, we found consistent significant associations between AMIs and influenza activity, but not between ischaemic strokes and influenza. Associations between influenza and AMI increased with age, were greatest in those aged >80 years, and were present in all geographical regions. In addition, the natural experiment provided by the second wave of the influenza pandemic in 2009 provided further evidence of the relationship between influenza and AMI, because both series peaked in the same non-winter month.


Subject(s)
Influenza, Human/epidemiology , Myocardial Infarction/epidemiology , Seasons , Stroke/epidemiology , Adult , Age Factors , Aged , Aged, 80 and over , Brain Ischemia/complications , Brain Ischemia/epidemiology , Humans , Incidence , Middle Aged , Models, Statistical , Pandemics , Regression Analysis , Stroke/etiology , United States/epidemiology
2.
Mini Rev Med Chem ; 7(1): 31-8, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17266635

ABSTRACT

Leptin, a peptide secreted by the white adipose tissue, circulates to the central nervous system and signals the status of body energy stores, regulating feeding behavior and energy balance. As human obesity is characterized by hyperleptinemia and leptin resistance, increasing leptin sensitivity is an attractive target for obesity treatment.


Subject(s)
Leptin/physiology , Humans , Leptin/genetics , Leptin/therapeutic use , Lipid Metabolism , Obesity/drug therapy , Obesity/physiopathology , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/therapeutic use , Signal Transduction
3.
Acta Physiol Scand ; 177(3): 345-9, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12609005

ABSTRACT

AIM: This manuscript briefly reviews evidence and potential implications of a leptin-sympathetic-leptin feedback loop. RESULTS: Leptin increases sympathetic nerve activity to brown adipose tissue, kidney and other tissues. This action has implications for regulation of arterial pressure. In turn, there is evidence that sympathoadrenal stimulation inhibits leptin mRNA expression and secretion from white adipose tissue through beta adrenergic mechanisms. CONCLUSION: This sympathetic modulation of leptin expression has potential implications for regulation of body fat.


Subject(s)
Adipose Tissue/physiology , Blood Pressure/physiology , Feedback, Physiological/physiology , Leptin/physiology , Sympathetic Nervous System/physiology , Adrenergic beta-Agonists/administration & dosage , Epinephrine/physiology , Humans , Isoproterenol/administration & dosage , Kidney/physiology , Leptin/metabolism , Models, Biological , RNA, Messenger/analysis , Receptors, Adrenergic, beta/physiology , Receptors, Leptin
4.
Bioessays ; 23(12): 1095-9, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11746228

ABSTRACT

No other hormone has drawn more attention than leptin in recent studies on the control of appetite, body weight and obesity. This hormone is produced by adipose tissue and enters the brain via a saturable specific transport mechanism. Leptin acts in the hypothalamus to modulate food intake and heat production as well as several other neuroendocrine pathways. The mechanisms through which leptin exerts its central nervous effects are now better understood. Proopiomelanocortin- and neuropeptide Y-containing neurons in the hypothalamus have emerged as potent candidate mediators of leptin action. These two neuropeptides have been shown to exert opposing effects using different pathways. Recently, Cowley et al. (2001) described a new circuit in the regulation of neuronal activity by leptin with an interaction between these two pathways. These data add complexity to the mechanisms by which leptin achieves its effects in the central nervous system, but they also offer potential mechanisms to explain the phenomenon of leptin resistance observed in obesity.


Subject(s)
Central Nervous System/metabolism , Leptin/metabolism , Neuropeptide Y/metabolism , Signal Transduction/physiology , alpha-MSH/metabolism , Animals , Central Nervous System/physiology , Corticotropin-Releasing Hormone/metabolism , Hypothalamus/metabolism , Neurons/metabolism , Neurons/physiology , Pro-Opiomelanocortin/metabolism , alpha-MSH/physiology
5.
Hypertension ; 38(5): 1081-6, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11711501

ABSTRACT

Leptin decreases appetite and increases sympathetic nerve activity and arterial pressure. Recent reports suggest that leptin may also have peripheral vasodilator actions that would tend to reduce arterial pressure. We tested the hypothesis that the direct vascular actions of leptin oppose sympathetically mediated vasoconstriction. We evaluated the effects of intravenous leptin (1 mg/kg over 3 hours) on arterial pressure and mesenteric, hindlimb, and renal blood flows in conscious rats. We then tested whether blockade of nitric oxide or the sympathetic nervous system would unmask a pressor or depressor effect of leptin, consistent with direct vascular actions. Acute intravenous administration of leptin alone did not change arterial pressure or regional blood flows. This was despite a significant increase in lumbar sympathetic nerve activity. Administration of the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester significantly increased arterial pressure and caused vasoconstriction. However, leptin did not have any significant effect on hemodynamics in the presence of N(G)-nitro-L-arginine methyl ester despite continued sympathoactivation. alpha-Adrenoceptor blockade with prazosin alone or combined with yohimbine significantly decreased arterial pressure and caused vasodilation. Again, leptin did not have any effect on arterial pressure or regional blood flow in the presence of sympathetic blockade. These data demonstrate that leptin does not have vasodilator actions in vivo at concentrations that are sufficient to increase sympathetic nerve activity. The absence of a pressor effect of leptin-induced sympathetic activation may merely reflect the brief duration of leptin administration. These data support the concept that the chronic hemodynamic actions of leptin are likely to be related to sympathetic activation.


Subject(s)
Leptin/pharmacology , Nitric Oxide/metabolism , Sympathetic Nervous System/physiology , Vasoconstriction/drug effects , Adrenergic alpha-Antagonists/pharmacology , Animals , Blood Pressure/drug effects , Enzyme Inhibitors/pharmacology , Kidney/blood supply , Kidney/drug effects , Kidney/innervation , Male , Mesentery/blood supply , Mesentery/drug effects , Mesentery/innervation , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide/antagonists & inhibitors , Nitroprusside/pharmacology , Prazosin/pharmacology , Rats , Rats, Sprague-Dawley , Rats, Wistar , Regional Blood Flow , Sympathetic Nervous System/drug effects , Vasodilator Agents/pharmacology , Yohimbine/pharmacology
6.
Hypertension ; 38(3): 384-8, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11566909

ABSTRACT

Leptin and corticotrophin-releasing factor increase sympathetic nervous activity to interscapular brown adipose tissue, kidneys, and adrenal glands. Leptin is known to increase hypothalamic corticotrophin-releasing factor. In this study, we tested the hypothesis that leptin-dependent increases in sympathetic nervous activity are mediated through increases in central nervous system corticotrophin-releasing factor activity. We examined the effects of intracerebroventricular administration of corticotrophin-releasing factor and intravenous leptin on sympathetic nervous activity to interscapular brown adipose tissue through multifiber neurography in anesthetized Sprague-Dawley rats pretreated with intracerebroventricular alpha-helical corticotrophin-releasing factor(9-41) (corticotrophin-releasing factor receptor antagonist) or vehicle. Centrally administered corticotrophin-releasing factor substantially increased interscapular brown adipose tissue sympathetic nervous activity. The responses to corticotrophin-releasing factor were substantially attenuated in animals pretreated with alpha-helical corticotrophin-releasing factor(9-41). Leptin-dependent increases in interscapular brown adipose tissue sympathetic nervous activity were significantly inhibited by pretreatment with alpha-helical corticotrophin-releasing factor(9-41). Interestingly, leptin also significantly increased arterial pressure over 6 hours, but this pressor action was not attenuated by the corticotrophin-releasing factor receptor antagonist. These results suggest that corticotrophin-releasing factor may mediate the sympathoexcitatory effect of leptin on thermogenic tissue without altering its cardiovascular actions.


Subject(s)
Blood Pressure/drug effects , Corticotropin-Releasing Hormone/pharmacology , Leptin/pharmacology , Sympathetic Nervous System/drug effects , Adipose Tissue, Brown/drug effects , Adipose Tissue, Brown/metabolism , Animals , Blood Pressure/physiology , Corticotropin-Releasing Hormone/physiology , Hormone Antagonists/pharmacology , Injections, Intraventricular , Leptin/physiology , Male , Peptide Fragments/pharmacology , Rats , Rats, Sprague-Dawley , Receptors, Corticotropin-Releasing Hormone/antagonists & inhibitors , Receptors, Corticotropin-Releasing Hormone/physiology , Sympathetic Nervous System/physiology , Time Factors
7.
Ultrasound Med Biol ; 27(6): 757-60, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11516535

ABSTRACT

We used bilateral transcranial Doppler to monitor the number of microembolic events (ME) in the left and right middle cerebral arteries of 29 patients during cardiac surgery that required extracorporeal circulation. Based on a previously published study, we hypothesized that the commonly used method of doubling unilateral ME counts to obtain an estimated bihemispheric load would result in significant errors of estimation. In our sample, estimated bihemispheric counts were inaccurate by an average of 18% (range 0--80%). Despite this large range of error, calculation of Cronbach's alpha revealed that actual error due to unreliability (4%) was small relative to the large variation in ME counts across subjects in this patient series. These findings suggest that unilateral monitoring is sufficient when the goal is to characterize a given subject's ME load within the context of the other subjects in the sample. However, when precise ME counts are required, bilateral monitoring is essential.


Subject(s)
Cardiac Surgical Procedures , Intracranial Embolism/diagnostic imaging , Monitoring, Intraoperative , Ultrasonography, Doppler, Transcranial , Cardiac Surgical Procedures/adverse effects , Diagnostic Errors , Extracorporeal Circulation/adverse effects , Female , Humans , Intracranial Embolism/etiology , Intraoperative Complications/diagnostic imaging , Male , Middle Aged , Middle Cerebral Artery/diagnostic imaging , Ultrasonography, Doppler, Transcranial/methods
8.
Am J Hypertens ; 14(7 Pt 1): 615-8, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11465643

ABSTRACT

Leptin is a protein produced by adipocytes. Leptin is known to markedly and rapidly increase sympathetic nerve activity to the kidney and hindlimb of experimental animals. Recent studies suggest that leptin may stimulate endothelial production of nitric oxide, which could oppose sympathetically induced vasoconstriction. We tested the hypothesis that such actions of leptin may produce peripheral functional sympatholysis. In Sprague-Dawley rats, we intermittently stimulated the abdominal sympathetic trunk and measured renal and hindlimb blood flows before and after 3 h of infusion of leptin (1000 microg/kg, n = 7) or vehicle (n = 7). Leptin did not change arterial pressure, heart rate, or renal or hindlimb conductance over the course of 3 h. In addition, leptin did not significantly alter sympathetically mediated vasomotor responses to electrical stimulation, as compared with vehicle. Thus, we conclude that leptin does not change regional blood flows, and that leptin also does not appear to have vascular or neural actions to cause peripheral functional sympatholysis.


Subject(s)
Leptin/pharmacology , Sympathetic Nervous System/drug effects , Animals , Blood Pressure/drug effects , Electric Stimulation , Heart Rate/drug effects , Hindlimb/blood supply , Male , Rats , Rats, Sprague-Dawley , Regional Blood Flow/drug effects , Splanchnic Nerves/drug effects , Splanchnic Nerves/physiology , Sympathetic Nervous System/physiology , Vasodilation/drug effects
9.
Am J Cardiol ; 88(3): 285-90, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11472709

ABSTRACT

We tested if vitamin E, a fat-soluble antioxidant, prevents resistance vessel endothelial dysfunction caused by methionine-induced hyperhomocysteinemia in humans. Moderate elevations in plasma homocysteine concentrations are associated with atherosclerosis and hypertension. Homocysteine causes endothelial dysfunction possibly through several mechanisms. No previous study has tested if a fat-soluble antioxidant can prevent endothelial dysfunction caused by experimental hyperhomocysteinemia. Ten healthy subjects participated in a 2 x 2 factorial, double-blind crossover study, receiving L-methionine (100 mg/kg at -6 hours) or vehicle, with and without vitamin E (1,200 IU at -13 hours). Endothelial function of forearm resistance vessels was assessed using forearm blood flow responses to brachial artery administration of endothelium-dependent and endothelium-independent agents. Forearm resistance vessel dilatation to acetylcholine was significantly impaired 7 hours after methionine (placebo, 583 +/- 87% vs methionine 30 +/- 68%; p <0.05). Dilatation to bradykinin was also impaired (placebo, 509 +/- 54% vs methionine 289 +/- 48%; p <0.05). Methionine did not alter vasodilatation to the endothelium-independent vasodilators, nitroprusside, and verapamil. Methionine-induced impairment of resistance vessel dilatation to acetylcholine and bradykinin (p <0.05 vs placebo) was prevented by administration of vitamin E (acetylcholine, p = 0.004; bradykinin, p = 0.004; both vs methionine alone). Experimentally increasing plasma homocysteine concentrations by oral methionine rapidly impairs resistance vessel endothelial function in healthy humans and this effect is reversed with administration of the fat-soluble antioxidant, vitamin E.


Subject(s)
Endothelium, Vascular/drug effects , Hyperhomocysteinemia/physiopathology , Vascular Resistance/drug effects , Vitamin E/pharmacology , Adult , Cross-Over Studies , Double-Blind Method , Endothelium, Vascular/physiology , Female , Humans , Hyperhomocysteinemia/chemically induced , Male , Methionine , Regional Blood Flow/drug effects , Vascular Resistance/physiology , Vasodilation/drug effects
10.
Diabetes ; 50(5): 1119-25, 2001 May.
Article in English | MEDLINE | ID: mdl-11334416

ABSTRACT

Adrenergic responsiveness to acute hypoglycemia is impaired after prior episodes of hypoglycemia. Although circulating epinephrine responses are blunted, associated alterations in adrenal sympathetic nerve activity (SNA) have not been reported. We examined adrenal nerve traffic in normal conscious rats exposed to acute insulin-induced hypoglycemia compared with insulin with (clamped) euglycemia. We also examined adrenal SNA and catecholamine responses to insulin-induced hypoglycemia in normal conscious rats after two antecedent episodes of hypoglycemia (days -2 and -1) compared with prior episodes of sham treatment. Acute insulin-induced hypoglycemia increased adrenal sympathetic nerve traffic compared with insulin administration with clamped euglycemia (165 +/- 12 vs. 118 +/- 21 spikes/s [P < 0.05]; or to 138 +/- 8 vs. 114 +/- 10% of baseline [P < 0.05]). In additional experiments, 2 days of antecedent hypoglycemia (days -2 and -1) compared with sham treatment significantly enhanced baseline adrenal SNA measured immediately before subsequent acute hypoglycemia on day 0 (180 +/- 11 vs. 130 +/- 12 spikes/s, respectively; P < 0.005) and during subsequent acute hypoglycemia (229 +/- 17 vs. 171 +/- 16 spikes/s; P < 0.05). However, antecedent hypoglycemia resulted in a nonsignificant reduction in hypoglycemic responsiveness of adrenal SNA when expressed as percent increase over baseline (127 +/- 5% vs. 140 +/- 14% of baseline). Antecedent hypoglycemia, compared with sham treatment, resulted in diminished epinephrine responsiveness to subsequent hypoglycemia. Norepinephrine responses to hypoglycemia were not significantly altered by antecedent hypoglycemia. In summary, prior hypoglycemia in normal rats increased adrenal sympathetic tone, but impaired epinephrine responsiveness to acute hypoglycemia. Hence, these data raise the intriguing possibility that increased sympathetic tone resulting from antecedent hypoglycemia downregulates subsequent epinephrine responsiveness to hypoglycemia. Alternatively, it is possible that the decrease in epinephrine responsiveness after antecedent hypoglycemia could be the result of reduced adrenal sympathetic nerve responsiveness.


Subject(s)
Adrenal Glands/innervation , Epinephrine/blood , Hypoglycemia/physiopathology , Insulin/pharmacology , Norepinephrine/blood , Sympathetic Nervous System/physiology , Animals , Blood Glucose/drug effects , Blood Glucose/metabolism , Blood Pressure/drug effects , Heart Rate/drug effects , Hypoglycemia/chemically induced , Rats , Rats, Sprague-Dawley , Sympathetic Nervous System/physiopathology , Time Factors
11.
Hypertension ; 37(3): 936-42, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11244021

ABSTRACT

Systemic leptin increases energy expenditure through sympathetic mechanisms, decreases appetite, and increases arterial pressure. We tested the hypothesis that the pressor action of leptin is mediated by the central nervous system. The interaction of dietary salt with leptin was also studied. Leptin was infused for 2 to 4 weeks into the third cerebral ventricle of Sprague-Dawley rats. Arterial pressure was measured by radiotelemetry. To control for the effects of leptin on body weight, vehicle-treated rats were pair-fed to the leptin group. Intracerebroventricular infusion of leptin at 200 ng/h in salt-depleted rats caused a reduction in food intake, weight loss, tachycardia, and decreased arterial pressure. Leptin at 1000 ng/h caused further reduction in food intake, weight loss, and tachycardia and prevented the hypotensive effect of weight loss observed in pair-fed, vehicle-treated animals. Intracerebroventricular leptin at 1000 ng/h in high-salt-fed rats also caused a sustained pressor response (+3+/-1 mm Hg), but high-salt intake did not potentiate the pressor effect of leptin. Intracerebroventricular leptin potentiated the pressor effect of air-jet stress. Intravenous administration of the same dose of leptin (1000 ng/h) did not change weight or arterial pressure, suggesting a direct central nervous system action. In contrast, a high dose of intravenous leptin (18 000 ng/h) caused weight loss and prevented the depressor effect of weight loss. In conclusion, this study demonstrates that high-dose leptin increases arterial pressure and heart rate through central neural mechanisms but leptin does not enhance salt sensitivity of arterial pressure. Leptin appears to oppose the depressor effect of weight loss.


Subject(s)
Central Nervous System/drug effects , Leptin/pharmacology , Animals , Blood Pressure/drug effects , Body Weight/drug effects , Central Nervous System/physiology , Diet, Sodium-Restricted , Dose-Response Relationship, Drug , Eating/drug effects , Heart Rate/drug effects , Injections, Intraventricular , Leptin/blood , Leptin/cerebrospinal fluid , Leptin/toxicity , Male , Rats , Rats, Sprague-Dawley , Sodium Chloride/administration & dosage , Stress, Physiological/physiopathology , Tachycardia/chemically induced , Telemetry
12.
Nephrol Dial Transplant ; 16(2): 295-301, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11158403

ABSTRACT

BACKGROUND: Endothelin-1 (ET-1), acting mainly through the ET(A) receptor, is a potent endothelium-derived vasoconstrictor peptide. Circulating concentrations of ET-1 are increased in chronic renal failure (CRF) and may influence vascular tone. METHODS: We investigated dorsal hand vein responsiveness to local infusion of ET-1 and noradrenaline in 12 hypertensive and 12 normotensive CRF patients and in 12 age and sex matched control subjects. We also investigated dorsal hand vein responses to the ET(A) receptor antagonist, BQ-123, and the endothelium-independent vasodilator glyceryl trinitrate (GTN), in six patients with CRF. RESULTS: The dose of noradrenaline causing a 50% of maximal vasoconstriction was similar in the hypertensive (32+/-11 pmol/min) and normotensive (26+/-7 pmol/min) CRF patients and control subjects (21+/-6 pmol/min). Vasoconstriction to ET-1 (5 pmol/min) was similar in CRF patients as a whole (AUC 35+/-5%) and controls (32+/-4%; P=0.70). However, venoconstriction was significantly less in hypertensive (23+/-6%) than in normotensive CRF patients (48+/-8%; P=0.01). Overall, venoconstriction to ET-1 correlated inversely with mean arterial blood pressure in the CRF patients (R=-0.43, P=0.04). In addition, basal vein size was smaller, and plasma endothelin concentrations greater, in the hypertensive CRF group. However, infusion of BQ-123 or GTN did not cause venodilatation in these subjects. CONCLUSIONS: These studies are consistent with the hypothesis that elevated plasma ET-1 contributes to vascular tone, and elevated blood pressure, in hypertensive CRF patients, and is associated with vascular receptor downregulation consequent on the increased exposure to ET-1. The reduced vein size in CRF patients appears to be structural rather than functional in nature. Further long-term studies with endothelin antagonists are required to determine the pathophysiological role of ET-1 in the altered structure and function of blood vessels in patients with CRF.


Subject(s)
Endothelin-1/pharmacology , Hand/blood supply , Hypertension/complications , Hypertension/physiopathology , Kidney Failure, Chronic/complications , Kidney Failure, Chronic/physiopathology , Norepinephrine/pharmacology , Vasoconstrictor Agents/pharmacology , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Vasoconstriction , Veins/drug effects
13.
Clin Sci (Lond) ; 100(2): 161-7, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11171285

ABSTRACT

Hyperhomocyst(e)inaemia is associated with endothelial dysfunction in animals and humans. Mechanisms responsible for endothelial dysfunction in hyperhomocyst(e)inaemia are poorly understood, but may involve impaired bioavailability of endothelium-derived nitric oxide (NO). We hypothesized that acute elevation of homocyst(e)ine by oral methionine loading may stimulate the formation of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of NO synthase, due to a transmethylation reaction during the formation of homocyst(e)ine from methionine. We studied nine healthy human subjects (five males, four females) aged 29+/-2 years. Flow-mediated vasodilation (FMD) in the brachial artery (endothelium-dependent) and vasodilation induced by nitroglycerine (endothelium-independent) were measured with high-resolution ultrasound before and 8 h after oral methionine (100 mg/kg in cranberry juice) or placebo (cranberry juice), on separate days and in random order. Plasma homocyst(e)ine and ADMA concentrations were measured by specific HPLC methods. After a methionine bolus, elevation of homocyst(e)ine (28.4+/-3.5 micromol/l) was associated with an increased plasma concentration of ADMA (2.03+/-0.18 micromol/l) and reduced FMD (1.54+/-0.92%). Placebo had no effect on these parameters. There was a significant inverse linear relationship between ADMA concentration and FMD (r=-0.49; P<0.05), which was stronger than the relationship between the homocyst(e)ine concentration and FMD (r=-0.36; not significant). We conclude that acute elevation of the homocyst(e)ine concentration impairs vascular endothelial function by a mechanism in which an elevated concentration of ADMA may be involved. This finding may have importance for understanding the mechanism(s) leading to homocyst(e)ine-associated vascular disease, and its potential treatment.


Subject(s)
Arginine/blood , Endothelium, Vascular/physiopathology , Hyperhomocysteinemia/physiopathology , Acute Disease , Adult , Arginine/analogs & derivatives , Brachial Artery/physiopathology , Cross-Over Studies , Double-Blind Method , Endothelium, Vascular/drug effects , Female , Homocysteine/blood , Humans , Hyperhomocysteinemia/blood , Hyperhomocysteinemia/chemically induced , Male , Methionine , Nitroglycerin/pharmacology , Vasodilation/physiology , Vasodilator Agents/pharmacology
14.
Am J Cardiol ; 85(3): 381-5, 2000 Feb 01.
Article in English | MEDLINE | ID: mdl-11078311

ABSTRACT

A single high-fat meal transiently impairs conduit vessel endothelial function. We tested the hypothesis that transient moderate hypertriglyceridemia by consumption of a high-fat meal impairs forearm resistance vessel endothelial function. Fifteen healthy persons consumed isocaloric high- and low-fat meals (900 calories, 50 and 4 g of fat, respectively) on 2 separate days. Endothelial function in forearm resistance vessels was assessed using blood flow responses to local intra-arterial infusion of nitroprusside, acetylcholine, bradykinin, and verapamil from 1 to 3 hours after the meal. Serum triglycerides increased from 112 +/- 15 mg/dl preprandially to 165 +/- 20 mg/dl 4 hours after the high-fat meal, which was a significantly larger increase than levels after the low-fat meal (p = 0.01). Total cholesterol, high-density lipoprotein, low-density lipoprotein, and very low density lipoprotein (VLDL) cholesterol concentrations did not change. There was no difference between high- and low-fat meals in vasodilation to the endothelium-dependent agents acetylcholine (low fat, 337 +/- 47%; high fat, 356 +/- 88%; p = 0.81) and bradykinin (low fat, 312 +/- 39%; high fat, 403 +/- 111%; p = 0.28), or to the endothelium-independent vasodilators nitroprusside (low fat, 313 +/- 27%; high fat, 355 +/- 42%; p = 0.31) and verapamil (low fat, 292 +/- 48%; high fat, 299 +/- 36%; p = 0.18). Thus, transient hypertriglyceridemia due to a high-fat meal does not impair resistance vessel endothelial function. These data contrast with previous studies in conduit vessels that showed substantial endothelial dysfunction. Therefore, although high-fat intake may contribute to large artery atherosclerosis, it probably does not predispose to hypertension or ischemia through resistance vessel dysfunction. The results suggest that the mechanism by which triglyceride-rich lipoproteins impair endothelial function in conduit vessels is not operative in resistance vessels.


Subject(s)
Dietary Fats/administration & dosage , Endothelium, Vascular/physiology , Hypertriglyceridemia/physiopathology , Vascular Resistance/drug effects , Vasodilator Agents/pharmacology , Acetylcholine/pharmacology , Adult , Bradykinin/pharmacology , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Endothelium, Vascular/drug effects , Forearm/blood supply , Humans , Male , Nitroprusside/pharmacology , Postprandial Period , Reference Values , Regional Blood Flow , Triglycerides/blood , Verapamil/pharmacology
15.
Circulation ; 102(21): 2607-10, 2000 Nov 21.
Article in English | MEDLINE | ID: mdl-11085964

ABSTRACT

BACKGROUND: Patients with obstructive sleep apnea (OSA) experience repetitive episodic hypoxemia with consequent sympathetic activation and marked blood pressure surges, each of which may impair endothelial function. We tested the hypothesis that patients with OSA have impaired endothelium-dependent vasodilation, even in the absence of overt cardiovascular disease. METHODS AND RESULTS: We studied 8 patients with OSA (age 44+/-4 years) and 9 obese control subjects (age 48+/-3 years). Patients with OSA were newly diagnosed, never treated for OSA, on no medications, and free of any other known diseases. All obese control subjects underwent complete overnight polysomnographic studies to exclude occult OSA. Resistance-vessel function was tested by use of forearm blood flow responses to intra-arterial infusions of acetylcholine (a vasodilator that stimulates endothelial release of nitric oxide), sodium nitroprusside (an exogenous nitric oxide donor), and verapamil (a calcium channel blocker). Conduit-vessel function was also evaluated by ultrasonography. Brachial artery diameter was measured under baseline conditions, during reactive hyperemia (with flow increase causing endothelium-dependent dilatation), and after sublingual administration of nitroglycerin (an endothelium-independent vasodilator). Patients with OSA had a blunted vasodilation in response to acetylcholine (P:<0.007), but responses to sodium nitroprusside and verapamil were not significantly different from those of control subjects. No significant difference in conduit-vessel dilation was evident between OSA patients and obese control subjects. CONCLUSIONS: Patients with OSA have an impairment of resistance-vessel endothelium-dependent vasodilation. This may be implicated in the pathogenesis of hypertension and heart failure in this condition.


Subject(s)
Endothelium, Vascular/physiopathology , Obesity/physiopathology , Sleep Apnea, Obstructive/physiopathology , Vascular Resistance , Vasodilation , Acetylcholine/administration & dosage , Adult , Blood Flow Velocity/drug effects , Brachial Artery/diagnostic imaging , Brachial Artery/drug effects , Dose-Response Relationship, Drug , Electrocardiography , Forearm/blood supply , Forearm/diagnostic imaging , Heart Rate/drug effects , Humans , Hyperemia/physiopathology , Infusions, Intra-Arterial , Male , Middle Aged , Obesity/complications , Polysomnography , Sleep Apnea, Obstructive/complications , Ultrasonography , Vascular Resistance/drug effects , Vasodilation/drug effects , Vasodilator Agents/administration & dosage
16.
Curr Hypertens Rep ; 2(3): 311-8, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10981165

ABSTRACT

Leptin is a protein produced by adipose tissue that acts in the central nervous system (CNS) to decrease appetite and increase energy expenditure. Leptin thus functions as the afferent component of a negative feedback loop that maintains stable adipose tissue mass. Intravenous leptin increases norepinephrine turnover and sympathetic nerve activity to thermogenic brown adipose tissue. Leptin also increases sympathetic nerve activity to tissues not usually considered thermogenic, including the kidney, hindlimb, and adrenal gland. Chronic systemic CNS administration of leptin increases arterial pressure and heart rate in conscious animals. However, leptin has additional cardiovascular actions that may act to oppose sympathetically mediated vasoconstriction. These actions include natriuresis, insulin sensitization, endothelium-dependent dilatation, and angiogenesis. Thus, the overall effect of leptin on arterial pressure has been unclear. Recent studies have demonstrated that leptin-deficient ob/ob obese mice have lower arterial pressure than lean controls with normal leptin levels. These studies suggest that leptin contributes physiologically to maintenance of arterial pressure. Leptin expression and plasma leptin concentrations are elevated in obese humans. Abnormalities in the generation or actions of leptin may, therefore, have implications for the sympathetic, cardiovascular, and renal changes associated with obesity.


Subject(s)
Brain/physiopathology , Hypertension/physiopathology , Leptin/physiology , Adipose Tissue/physiology , Adrenal Glands/drug effects , Adrenergic alpha-Agonists/metabolism , Animals , Appetite/physiology , Blood Pressure/drug effects , Energy Metabolism/physiology , Heart Rate/drug effects , Humans , Kidney/drug effects , Leptin/blood , Leptin/genetics , Leptin/pharmacology , Mice , Mice, Obese , Norepinephrine/metabolism , Obesity/blood , Obesity/physiopathology , Sympathetic Nervous System/drug effects , Vasodilator Agents/pharmacology
17.
Clin Pharmacol Ther ; 68(1): 67-74, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10945317

ABSTRACT

BACKGROUND: Endothelin-3 (ET-3) and its inactive precursor, big endothelin-3 (big ET-3), are both found in human plasma. We investigated whether big ET-3 is converted to ET-3 in the human forearm resistance vessels and dorsal hand veins in vivo. METHODS: In a 4-phase study, 6 subjects received 90 minute intrabrachial artery infusions of big ET-3 (50 and 100 pmol x min(-1)) and ET-3 (5 and 10 pmol x min(-1)) in random order. Forearm blood flow was measured by venous occlusion plethysmography. In a second 3-phase study, 6 subjects received 90-minute dorsal hand vein infusions of saline solution, big ET-3 (50 pmol x min(-1)) and ET-3 (5 pmol x min(-1)) in random order. In a third 2-phase study, 6 subjects received 90-minute dorsal hand vein infusions of big ET-3 (100 pmol x min(-1)) and ET-3 (10 pmol x min(-1)). In the dorsal hand vein studies, vessel diameter was measured by the Aellig technique. RESULTS: Intra-arterial ET-3 caused local forearm vasoconstriction of 20%+/-9% (P = .009) at 5 pmol x min(-1) and 20%+/-10% (P = .001) at 10 pmol x min(-1) after 90 minutes, with no difference between doses (P = .69). Intra-arterial big ET-3 also caused local forearm vasoconstriction of 22%+/-6% at 50 pmol x min(-1) (P = .004) and 18%+/-3% at 100 pmol x min(-1) (P<.0001) after 90 minutes, with no difference between doses (P = .44). There were no significant differences between the responses to intra-arterial big ET-3 and ET-3 at these doses. Local intravenous ET-3 caused a constriction of 9%+/-2% at 5 pmol x min(-1) (P = .04) and 22%+/-8% at 10 pmol x min(-1) (P = .002) after 90 minutes. Big ET-3 at 50 pmol x min(-1) and 100 pmol x min(-1) did not affect hand vein tone. All responses were slowly progressive. CONCLUSIONS: Based on vasoconstriction, measurable conversion of big ET-3 to ET-3 occurs in forearm resistance vessels but not in dorsal hand veins in vivo. An endothelin-converting enzyme, capable of converting exogenously administered big ET-3 to ET-3, appears to be present in upper limb resistance arteries but not in capacitance vessels in humans.


Subject(s)
Endothelins/pharmacology , Forearm/blood supply , Hand/blood supply , Protein Precursors/pharmacology , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology , Adult , Endothelin-3/metabolism , Endothelins/administration & dosage , Endothelins/metabolism , Humans , Infusions, Intra-Arterial , Infusions, Intravenous , Male , Middle Aged , Protein Precursors/administration & dosage , Protein Precursors/metabolism , Reference Values , Regional Blood Flow/drug effects , Vasoconstrictor Agents/administration & dosage , Vasoconstrictor Agents/metabolism , Veins/drug effects
18.
Cardiovasc Res ; 47(1): 166-72, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10869543

ABSTRACT

OBJECTIVE: The relative importance of ETA and ETB receptors in mediating the constrictor effects of endogenous endothelin-1 in patients with chronic heart failure is not known. The primary purpose of this study was to compare the acute effects of selective ETA and ETB receptor antagonists in vivo in healthy subjects and patients with chronic heart failure. Our secondary aim was to examine more closely the effect of chronic heart failure on endothelin biosynthesis. METHODS: We studied the effects of BQ-123 (a selective ETA antagonist) and BQ-788 (a selective ETB antagonist) in ten healthy subjects and ten patients with chronic heart failure. Locally active doses of each antagonist were infused into the non-dominant brachial artery for 90 min on separate days at least 1 week apart. Changes in forearm blood flow were measured by venous occlusion plethysmography. Venous blood samples were obtained prior to antagonist infusion for assay of total endothelin, big endothelin-1 and C-terminal fragment immunoreactivity. RESULTS: BQ-123 (100 nmol/min) increased blood flow by 54+/-10% (P<0.001) and 30+/-5% (P<0.001) in controls and heart failure patients, respectively. BQ-788 (1 nmol/min) reduced blood flow by 15+/-5% (P=0. 036) and 9+/-4% (P=0.001) in controls and heart failure patients, respectively. Total endothelin immunoreactivity was non significantly greater in heart failure patients than controls (6. 8+/-1.4 vs. 4.6+/-0.5 pM; P=0.13). Big endothelin-1 (2.6+/-0.4 vs. 1. 7+/-0.1 pM; P=0.04) and C-terminal fragment immunoreactivity (2. 1+/-0.3 vs. 0.6+/-0.1 pM; P<0.0001) were each significantly greater in heart failure patients than controls. CONCLUSIONS: Selective ETA receptor antagonism caused vasodilatation in the peripheral circulation of healthy subjects and patients with chronic heart failure while selective ETB receptor antagonism caused vasoconstriction in each group. ETB receptor antagonism may therefore cause potentially deleterious vasoconstriction in chronic heart failure. Chronic heart failure is associated with a significant increase in plasma big endothelin-1 and C-terminal fragment immunoreactivity.


Subject(s)
Endothelin Receptor Antagonists , Heart Failure/metabolism , Oligopeptides , Peptides, Cyclic , Piperidines , Vasodilator Agents/pharmacology , Vasomotor System/drug effects , Case-Control Studies , Forearm/blood supply , Humans , Male , Plethysmography , Regional Blood Flow/drug effects
19.
Clin Sci (Lond) ; 98(1): 65-70, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10600660

ABSTRACT

Cardiac preload reduction through venodilatation is beneficial in chronic heart failure. The recent development of endothelin receptor antagonists for possible therapeutic use in heart failure has hastened the need for a clearer understanding of the venoconstrictor actions of endothelin-1 in this disease. Two main subtypes of endothelin receptor, ET(A) and ET(B), exist in human blood vessels. We studied the venoconstrictor effects of endothelin-1 (a non-selective ET(A) and ET(B) agonist) and sarafotoxin S6c (a selective ET(B) agonist) in vivo in patients with chronic heart failure and in age-matched healthy controls. On separate days at least 1 week apart, locally active doses of endothelin-1 or sarafotoxin S6c were infused into a suitable dorsal hand vein for 1 h, and the venous internal diameter was measured using a displacement technique. Venoconstriction in response to endothelin-1 was significantly blunted in heart failure patients compared with controls (26+/-7% and 51+/-6% peak reduction in vein calibre respectively; P=0.013). Venoconstriction to sarafotoxin S6c was similar in heart failure patients and controls (17+/-5% and 17+/-4% peak reduction in vein calibre respectively). Both ET(A) and ET(B) receptors mediate venoconstriction in healthy subjects and in patients with chronic heart failure. Optimal inhibition of the venoconstrictor effects of endothelin-1 in chronic heart failure may therefore require administration of an antagonist with ET(A)- and ET(B)-receptor-blocking properties. Chronic heart failure may be associated with a selective decrease in venous ET(A) receptor sensitivity, but further studies are required to clarify the functional significance of this observation.


Subject(s)
Endothelin Receptor Antagonists , Endothelin-1/pharmacology , Heart Failure/physiopathology , Vasoconstriction , Vasoconstrictor Agents/pharmacology , Viper Venoms/pharmacology , Aged , Analysis of Variance , Case-Control Studies , Endothelin-1/blood , Hand/blood supply , Heart Failure/blood , Humans , Infusions, Intravenous , Male , Receptor, Endothelin A , Receptor, Endothelin B , Receptors, Endothelin/physiology , Time Factors
20.
J Hypertens ; 17(10): 1395-401, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10526899

ABSTRACT

OBJECTIVE: There is limited information on the mechanisms mediating the deleterious effects of passive smoke exposure. Cross-sectional studies indicate that nonsmokers exposed chronically to passive smoke have impaired endothelium mediated vasodilation. We tested the hypothesis that acute exposure to sidestream (passive) smoke impairs endothelium-dependent vasodilation in healthy nonsmokers. METHODS AND RESULTS: We studied 12 healthy nonsmokers (aged 27 +/- 5 years, nine men and three women). We obtained measurements of blood pressure, heart rate, and bilateral forearm blood flow (FBF). Each individual was studied twice, following a randomized, placebo-controlled design. The effects of passive smoke were studied on one day and the effects of vehicle (room air) on a separate day. Acetylcholine (ACh) and sodium nitroprusside (SNP) were infused into the left brachial artery before and after 15 min of exposure to either passive smoke (carbon monoxide concentration between 20 and 40 p.p.m.) or vehicle (room air). The order of ACh and SNP, and smoke or vehicle, was randomized between individuals. Smoke exposure increased carboxyhemoglobin from 0.5 +/- 0.1 % to 0.8 +/- 0.1% (P= 0.002). Neither passive smoke nor vehicle changed baseline measurements of heart rate, blood pressure and forearm vascular resistance (FVR). The vasodilatory responses to ACh and SNP were very similar, both before and after exposure to passive smoke and before and after vehicle. CONCLUSION: Our data demonstrate that acute exposure to passive smoke does not alter either endothelium-dependent or independent vasodilatory responses in healthy nonsmoking individuals. Hence, impaired endothelial vasodilatory responses in nonsmokers chronically exposed to passive smoke most likely reflect chronic functional and/or structural changes in responses to cigarette smoke, rather than the acute effects of cigarette smoke toxicity on endothelial function.


Subject(s)
Blood Pressure/drug effects , Heart Rate/drug effects , Regional Blood Flow/drug effects , Tobacco Smoke Pollution/adverse effects , Vasodilation/drug effects , Acetylcholine/pharmacology , Adult , Cross-Sectional Studies , Endothelium, Vascular/physiopathology , Female , Forearm/blood supply , Humans , Male , Nitroprusside/pharmacology , Time Factors , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...